UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

被引：4
|
作者：
Peeters, Sofia L. J. [1 ,2 ]
Deenen, Maarten J. [1 ,2 ]
Thijs, Anna M. J. [3 ]
Hulshof, Emma C. [1 ,2 ]
Mathijssen, Ron H. J. [4 ]
Gelderblom, Hans [5 ]
Guchelaar, Henk-Jan [2 ]
Swen, Jesse J. [2 ]
机构：
[1] Catharina Hosp, Dept Clin Pharm, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Catharina Hosp, Dept Med Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[4] Erasmus MC, Dept Med Oncol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 09期
关键词：
irinotecan; personalized medicine; PGx; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment; UGT1A1; PHARMACOGENETICS; IMPLEMENTATION; NEUTROPENIA; TOXICITY; THERAPY; RISK;
D O I：
10.2217/pgs-2023-0096
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care. © 2023 Future Medicine Ltd.
引用
收藏
页码：435 / 439
页数：5
相关论文
共 50 条
  • [21] Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
    Jian-Ming Xu
    Yan Wang
    Fei-Jiao Ge
    Li Lin
    Ze-Yuan Liu
    Manish R Sharma
    World Journal of Gastroenterology, 2013, 19 (24) : 3899 - 3903
  • [22] Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
    Innocenti, Federico
    Schilsky, Richard L.
    Ramirez, Jacqueline
    Janisch, Linda
    Undevia, Samir
    House, Larry K.
    Das, Soma
    Wu, Kehua
    Turcich, Michelle
    Marsh, Robert
    Karrison, Theodore
    Maitland, Michael L.
    Salgia, Ravi
    Ratain, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2328 - 2334
  • [23] Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
    Iwasa, Satoru
    Muro, Kei
    Morita, Satoshi
    Park, Young Suk
    Nakamura, Masato
    Kotaka, Masahito
    Nishina, Tomohiro
    Matsuoka, Hiroshi
    Ahn, Joong Bae
    Lee, Keun-Wook
    Hong, Yong Sang
    Han, Sae Won
    Cho, Sang-Hee
    Zhang, Dong-Sheng
    Fang, Wei-Jia
    Bai, Li
    Yuan, Xiang-Lin
    Yuan, Ying
    Yamada, Yasuhide
    Sakamoto, Junichi
    Kim, Tae Won
    CANCER SCIENCE, 2021, 112 (11) : 4669 - 4678
  • [24] Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab
    Gupta, Bhavna
    LeVea, Charles
    Litwin, Alan
    Fakih, Marwan G.
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 447 - 449
  • [25] Clinical Observations on Associations Between the UGT1A1 Genotype and Severe Toxicity of Irinotecan
    Lu, Yan-Yan
    Huang, Xin-En
    Wu, Xue-Yan
    Cao, Jie
    Liu, Jin
    Wang, Lin
    Xiang, Jin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (07) : 3335 - 3341
  • [26] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
    Hoskins, Janelle M.
    Goldberg, Richard M.
    Qu, Pingping
    Ibrahim, Joseph G.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1290 - 1295
  • [27] Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance
    Sorah, Jonathan D.
    Deal, Allison M.
    Stein, Sophia, I
    Jonsson, Mattias
    Innocenti, Federico
    Turk, Anita
    Boles, Jeremiah C.
    Irvin, William
    Basch, Ethan M.
    Sanoff, Hanna K.
    Wood, William A.
    ONCOLOGIST, 2024, 29 (09): : 780 - 785
  • [28] UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice
    Etienne-Grimaldi, Marie-Christine
    Boyer, Jean-Christophe
    Thomas, Fabienne
    Quaranta, Sylvie
    Picard, Nicolas
    Loriot, Marie-Anne
    Narjoz, Celine
    Poncet, Delphine
    Gagnieu, Marie-Claude
    Ged, Cecile
    Broly, Franck
    Le Morvan, Valerie
    Bouquie, Regis
    Gaub, Marie-Pierre
    Philibert, Laurent
    Ghiringhelli, Francois
    Le Guellec, Chantal
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (03) : 219 - 237
  • [29] Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
    Satoh, Taroh
    Ura, Takashi
    Yamada, Yasuhide
    Yamazaki, Kentaro
    Tsujinaka, Toshimasa
    Munakata, Masaki
    Nishina, Tomohiro
    Okamura, Shu
    Esaki, Taito
    Sasaki, Yasutsuna
    Koizumi, Wasaburo
    Kakeji, Yoshihiro
    Ishizuka, Naoki
    Hyodo, Ichinosuke
    Sakata, Yuh
    CANCER SCIENCE, 2011, 102 (10) : 1868 - 1873
  • [30] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
    Thu Nguyen, Cuc Thi
    Minh Thuy, Nguyen Thi
    Huong, Phung Thanh
    PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
12345